Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new user design in the French nationwide claims database.

Marine Gross-Goupil,N. Thurin,Magali Rouyer,Thibaud Haaser,Xavier Rebillard,Michel Soulie,Gérard de Pouvourville,Fatiha Messaoudi,Camille Capone,Emmanuelle Bignon,Jérémy Jové,Stéphanie Lamarque,Cécile Droz-Perroteau,Nicholas Moore,Patrick Blin

Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new user design in the French nationwide claims database.

2021

Marine Gross-Goupil
N. Thurin
Magali Rouyer
Thibaud Haaser
Xavier Rebillard
Michel Soulie
Gérard de Pouvourville
Fatiha Messaoudi
Camille Capone
Emmanuelle Bignon
Jérémy Jové
Stéphanie Lamarque
Cécile Droz-Perroteau
Nicholas Moore
Patrick Blin

91Background: Abiraterone acetate in association with prednisone/prednisolone and docetaxel can both be used as first or second line treatments for metastatic castration-resistant prostate cancer (...

Keywords:

Abiraterone acetate
claims database
Prednisone
Prostate cancer
Oncology
Docetaxel
castration resistant
Internal medicine
in patient
Prednisolone
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations